top of page
Backgrounds.jpg
Statesman-Examiner Logo 2025 with Shadow.png

Loading...

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AC Immune SA - Common Stock (NQ:ACIU)

2.415 +0.035 (+1.47%)
Streaming Delayed Price Updated: 1:29 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AC Immune SA - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
From AC Immune SA
Via GlobeNewswire
News headline image
ACIU Stock Earnings: AC Immune Beats EPS, Beats Revenue for Q4 2023 ↗
ACIU stock results show that AC Immune beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
News headline image
Why Shares of AC Immune Jumped This Week ↗
The FDA has granted a Fast Track Designation to its Alzheimer's disease vaccine candidate. 
Via The Motley Fool
News headline image
Why AC Immune Stock Skyrocketed Today ↗
AC Immune SA (NASDAQ: ACIU) shares surged Tuesday after the company received FDA Fast Track Designation for its anti-amyloid-beta active immunotherapy, ACI-24.060,  
Via Benzinga
News headline image
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Raises $50M, Its Alzheimer's Targeting Immunotherapy Advances Into Phase 2b Trial ↗
AC Immune SA's (NASDAQ: ACIU) development partner has programmed the launch of a Phase 2b clinical study to evaluate ACI-35.030 (JNJ-64042056) in patients with... 
Via Benzinga
News headline image
AC Immune Announces Pricing of Underwritten Offering of Common Shares
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
From AC Immune SA
Via GlobeNewswire
News headline image
Penny Stock Powerhouses: 7 Picks Poised for Explosive Growth ↗
Although growth penny stocks present extraordinary risks, if you exercise meticulous care, these ideas might be worth a shot. 
Via InvestorPlace
News headline image
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others ↗
Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this  
Via Benzinga
News headline image
AC Immune to Present at the Jefferies 2023 London Healthcare Conference
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune SA Appoints New Chief Medical Officer
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Showcasing Precision Medicine Programs at AAIC 2023
From AC Immune SA
Via GlobeNewswire
News headline image
Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health. 
Via Benzinga
News headline image
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Holds Annual General Meeting of Shareholders
From AC Immune SA
Via GlobeNewswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
It's time to start the day with a breakdown of the biggest pre-market stock movers that traders need to know about for Thursday morning! 
Via InvestorPlace
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page